BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Vote In favor of Your Favored Web-based Visual depiction Administration- Vote in favor of your Number one Kind of Shades
- 7 Powerful Methods for forestalling Telephone Overheating: Keep Your Gadget Cool
- Pilot captures jaw-dropping northern lights show from 36,000 feet (photos)
- Vote In favor of Your Favored Treat
- The Delight of Perusing: Book Proposals for Each Class
- Jamaica reports deadly leptospirosis outbreak after Hurricane Melissa
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
